Levels of active tyrosine kinase receptor determine the tumor response to Zalypsis View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2014-04-23

AUTHORS

Victoria Moneo, Beatriz G Serelde, Carmen Blanco-Aparicio, Ramon Diaz-Uriarte, Pablo Avilés, Gemma Santamaría, Juan C Tercero, Carmen Cuevas, Amancio Carnero

ABSTRACT

BACKGROUND: Zalypsis(®) is a marine compound in phase II clinical trials for multiple myeloma, cervical and endometrial cancer, and Ewing's sarcoma. However, the determinants of the response to Zalypsis are not well known. The identification of biomarkers for Zalypsis activity would also contribute to broaden the spectrum of tumors by selecting those patients more likely to respond to this therapy. METHODS: Using in vitro drug sensitivity data coupled with a set of molecular data from a panel of sarcoma cell lines, we developed molecular signatures that predict sensitivity to Zalypsis. We verified these results in culture and in vivo xenograft studies. RESULTS: Zalypsis resistance was dependent on the expression levels of PDGFRα or constitutive phosphorylation of c-Kit, indicating that the activation of tyrosine kinase receptors (TKRs) may determine resistance to Zalypsis. To validate our observation, we measured the levels of total and active (phosphorylated) forms of the RTKs PDGFRα/β, c-Kit, and EGFR in a new panel of diverse solid tumor cell lines and found that the IC50 to the drug correlated with RTK activation in this new panel. We further tested our predictions about Zalypsis determinants for response in vivo in xenograft models. All cells lines expressing low levels of RTK signaling were sensitive to Zalypsis in vivo, whereas all cell lines except two with high levels of RTK signaling were resistant to the drug. CONCLUSIONS: RTK activation might provide important signals to overcome the cytotoxicity of Zalypsis and should be taken into consideration in current and future clinical trials. More... »

PAGES

281-281

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/1471-2407-14-281

DOI

http://dx.doi.org/10.1186/1471-2407-14-281

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1017901424

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/24758355


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biomarkers, Pharmacological", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Line, Tumor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Resistance, Neoplasm", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "ErbB Receptors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Gene Expression Regulation, Neoplastic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proto-Oncogene Proteins c-kit", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "RNA, Messenger", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptor, Platelet-Derived Growth Factor alpha", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptor, Platelet-Derived Growth Factor beta", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sarcoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tetrahydroisoquinolines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Xenograft Model Antitumor Assays", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "PharmaMar R & D, Madrid, Spain", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "PharmaMar R & D, Madrid, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Moneo", 
        "givenName": "Victoria", 
        "id": "sg:person.0625224764.89", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0625224764.89"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Experimental Therapeutics Programme, Spanish National Cancer Center (CNIO), Madrid, Spain", 
          "id": "http://www.grid.ac/institutes/grid.7719.8", 
          "name": [
            "Experimental Therapeutics Programme, Spanish National Cancer Center (CNIO), Madrid, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Serelde", 
        "givenName": "Beatriz G", 
        "id": "sg:person.01047632264.90", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01047632264.90"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Experimental Therapeutics Programme, Spanish National Cancer Center (CNIO), Madrid, Spain", 
          "id": "http://www.grid.ac/institutes/grid.7719.8", 
          "name": [
            "Experimental Therapeutics Programme, Spanish National Cancer Center (CNIO), Madrid, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Blanco-Aparicio", 
        "givenName": "Carmen", 
        "id": "sg:person.01300502421.68", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01300502421.68"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Structural Biology and Biocomputing Programme, Spanish National Cancer Center (CNIO), Madrid, Spain", 
          "id": "http://www.grid.ac/institutes/grid.7719.8", 
          "name": [
            "Structural Biology and Biocomputing Programme, Spanish National Cancer Center (CNIO), Madrid, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Diaz-Uriarte", 
        "givenName": "Ramon", 
        "id": "sg:person.01135361171.83", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01135361171.83"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "PharmaMar R & D, Madrid, Spain", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "PharmaMar R & D, Madrid, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Avil\u00e9s", 
        "givenName": "Pablo", 
        "id": "sg:person.0730234600.98", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0730234600.98"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "PharmaMar R & D, Madrid, Spain", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "PharmaMar R & D, Madrid, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Santamar\u00eda", 
        "givenName": "Gemma", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "PharmaMar R & D, Madrid, Spain", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "PharmaMar R & D, Madrid, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tercero", 
        "givenName": "Juan C", 
        "id": "sg:person.01367534053.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01367534053.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "PharmaMar R & D, Madrid, Spain", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "PharmaMar R & D, Madrid, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cuevas", 
        "givenName": "Carmen", 
        "id": "sg:person.0742563255.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0742563255.13"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocio, Edificio IBIS, Consejo Superior de Investigaciones Cientificas, Avda. Manuel Siurot s/n., Sevilla 41013, Spain", 
          "id": "http://www.grid.ac/institutes/grid.411109.c", 
          "name": [
            "Instituto de Biomedicina de Sevilla, IBIS/Hospital Universitario Virgen del Rocio/CSIC/Universidad de Sevilla, Sevilla, Spain", 
            "Consejo Superior de Investigaciones Cientificas, Sevilla, Spain", 
            "Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocio, Edificio IBIS, Consejo Superior de Investigaciones Cientificas, Avda. Manuel Siurot s/n., Sevilla 41013, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Carnero", 
        "givenName": "Amancio", 
        "id": "sg:person.0634426643.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0634426643.41"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/nature04296", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028145633", 
          "https://doi.org/10.1038/nature04296"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/91008", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052456061", 
          "https://doi.org/10.1038/91008"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1210846", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040117116", 
          "https://doi.org/10.1038/sj.onc.1210846"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1205181", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002286113", 
          "https://doi.org/10.1038/sj.onc.1205181"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1471-2407-12-514", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045289283", 
          "https://doi.org/10.1186/1471-2407-12-514"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1207111", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041430673", 
          "https://doi.org/10.1038/sj.onc.1207111"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-008-0843-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033399730", 
          "https://doi.org/10.1007/s00280-008-0843-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1204984", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027899748", 
          "https://doi.org/10.1038/sj.onc.1204984"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00148581-200810050-00005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022748194", 
          "https://doi.org/10.2165/00148581-200810050-00005"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2014-04-23", 
    "datePublishedReg": "2014-04-23", 
    "description": "BACKGROUND: Zalypsis(\u00ae) is a marine compound in phase II clinical trials for multiple myeloma, cervical and endometrial cancer, and Ewing's sarcoma. However, the determinants of the response to Zalypsis are not well known. The identification of biomarkers for Zalypsis activity would also contribute to broaden the spectrum of tumors by selecting those patients more likely to respond to this therapy.\nMETHODS: Using in vitro drug sensitivity data coupled with a set of molecular data from a panel of sarcoma cell lines, we developed molecular signatures that predict sensitivity to Zalypsis. We verified these results in culture and in vivo xenograft studies.\nRESULTS: Zalypsis resistance was dependent on the expression levels of PDGFR\u03b1 or constitutive phosphorylation of c-Kit, indicating that the activation of tyrosine kinase receptors (TKRs) may determine resistance to Zalypsis. To validate our observation, we measured the levels of total and active (phosphorylated) forms of the RTKs PDGFR\u03b1/\u03b2, c-Kit, and EGFR in a new panel of diverse solid tumor cell lines and found that the IC50 to the drug correlated with RTK activation in this new panel. We further tested our predictions about Zalypsis determinants for response in vivo in xenograft models. All cells lines expressing low levels of RTK signaling were sensitive to Zalypsis in vivo, whereas all cell lines except two with high levels of RTK signaling were resistant to the drug.\nCONCLUSIONS: RTK activation might provide important signals to overcome the cytotoxicity of Zalypsis and should be taken into consideration in current and future clinical trials.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/1471-2407-14-281", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1024632", 
        "issn": [
          "1471-2407"
        ], 
        "name": "BMC Cancer", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "14"
      }
    ], 
    "keywords": [
      "tyrosine kinase receptors", 
      "clinical trials", 
      "cell lines", 
      "phase II clinical trial", 
      "future clinical trials", 
      "II clinical trials", 
      "kinase receptors", 
      "vivo xenograft studies", 
      "PDGFR\u03b1/\u03b2", 
      "spectrum of tumors", 
      "identification of biomarkers", 
      "sarcoma cell lines", 
      "endometrial cancer", 
      "multiple myeloma", 
      "tumor response", 
      "Ewing's sarcoma", 
      "xenograft studies", 
      "xenograft model", 
      "tumor cell lines", 
      "solid tumor cell lines", 
      "drug sensitivity data", 
      "RTK activation", 
      "expression levels", 
      "sarcoma", 
      "molecular signatures", 
      "trials", 
      "receptors", 
      "new panel", 
      "drugs", 
      "Zalypsis", 
      "activation", 
      "vivo", 
      "marine compounds", 
      "low levels", 
      "active form", 
      "kit", 
      "high levels", 
      "response", 
      "constitutive phosphorylation", 
      "levels", 
      "myeloma", 
      "patients", 
      "therapy", 
      "tumors", 
      "cancer", 
      "EGFR", 
      "PDGFR\u03b1", 
      "biomarkers", 
      "determinants", 
      "sensitivity data", 
      "important signal", 
      "IC50", 
      "panel", 
      "cytotoxicity", 
      "resistance", 
      "RTK", 
      "lines", 
      "phosphorylation", 
      "data", 
      "activity", 
      "study", 
      "sensitivity", 
      "culture", 
      "identification", 
      "results", 
      "compounds", 
      "observations", 
      "consideration", 
      "form", 
      "molecular data", 
      "model", 
      "signatures", 
      "signals", 
      "prediction", 
      "spectra", 
      "set", 
      "Zalypsis activity", 
      "Zalypsis resistance", 
      "RTKs PDGFR\u03b1/\u03b2", 
      "diverse solid tumor cell lines", 
      "Zalypsis determinants", 
      "cytotoxicity of Zalypsis", 
      "active tyrosine kinase receptor"
    ], 
    "name": "Levels of active tyrosine kinase receptor determine the tumor response to Zalypsis", 
    "pagination": "281-281", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1017901424"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/1471-2407-14-281"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "24758355"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/1471-2407-14-281", 
      "https://app.dimensions.ai/details/publication/pub.1017901424"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:34", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_639.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/1471-2407-14-281"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/1471-2407-14-281'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/1471-2407-14-281'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/1471-2407-14-281'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/1471-2407-14-281'


 

This table displays all metadata directly associated to this object as RDF triples.

297 TRIPLES      22 PREDICATES      131 URIs      114 LITERALS      20 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/1471-2407-14-281 schema:about N16b6428a6b9e41e9bf7fecdc23f2e240
2 N275072d834174d899b2cfd010242ad13
3 N3f96fc3685b74276b8e198b152346bfc
4 N5912e194a3cd411bbb44fea29ebf2c6d
5 N6eecc2f953774b3b9a19c27eea1b42ea
6 N7b18d15639684cc6800f6d87e9c9257d
7 N9cea90a27b944b1fa71890c7ded6d07b
8 Naefd942a482845a0a200df0838cefa6c
9 Nb9913c76f91942e7a463fe295a234d32
10 Nbde0aafb0ec146228ea12a3354db74c9
11 Ncccd093b01ce433489b1f62fb8ca1722
12 Nd1e3653907f944189b160f99e2b74d89
13 Nda822042e70b4d09b9b28db2d41c6c77
14 anzsrc-for:11
15 anzsrc-for:1112
16 schema:author N5ca76fd3219e4162b9d14b0e5366322c
17 schema:citation sg:pub.10.1007/s00280-008-0843-2
18 sg:pub.10.1038/91008
19 sg:pub.10.1038/nature04296
20 sg:pub.10.1038/sj.onc.1204984
21 sg:pub.10.1038/sj.onc.1205181
22 sg:pub.10.1038/sj.onc.1207111
23 sg:pub.10.1038/sj.onc.1210846
24 sg:pub.10.1186/1471-2407-12-514
25 sg:pub.10.2165/00148581-200810050-00005
26 schema:datePublished 2014-04-23
27 schema:datePublishedReg 2014-04-23
28 schema:description BACKGROUND: Zalypsis(®) is a marine compound in phase II clinical trials for multiple myeloma, cervical and endometrial cancer, and Ewing's sarcoma. However, the determinants of the response to Zalypsis are not well known. The identification of biomarkers for Zalypsis activity would also contribute to broaden the spectrum of tumors by selecting those patients more likely to respond to this therapy. METHODS: Using in vitro drug sensitivity data coupled with a set of molecular data from a panel of sarcoma cell lines, we developed molecular signatures that predict sensitivity to Zalypsis. We verified these results in culture and in vivo xenograft studies. RESULTS: Zalypsis resistance was dependent on the expression levels of PDGFRα or constitutive phosphorylation of c-Kit, indicating that the activation of tyrosine kinase receptors (TKRs) may determine resistance to Zalypsis. To validate our observation, we measured the levels of total and active (phosphorylated) forms of the RTKs PDGFRα/β, c-Kit, and EGFR in a new panel of diverse solid tumor cell lines and found that the IC50 to the drug correlated with RTK activation in this new panel. We further tested our predictions about Zalypsis determinants for response in vivo in xenograft models. All cells lines expressing low levels of RTK signaling were sensitive to Zalypsis in vivo, whereas all cell lines except two with high levels of RTK signaling were resistant to the drug. CONCLUSIONS: RTK activation might provide important signals to overcome the cytotoxicity of Zalypsis and should be taken into consideration in current and future clinical trials.
29 schema:genre article
30 schema:inLanguage en
31 schema:isAccessibleForFree true
32 schema:isPartOf N77fbe71aeec44ebfaf9d542c894c0a79
33 N7d789e3551f84f72a86266bea79e0729
34 sg:journal.1024632
35 schema:keywords EGFR
36 Ewing's sarcoma
37 IC50
38 II clinical trials
39 PDGFRα
40 PDGFRα/β
41 RTK
42 RTK activation
43 RTKs PDGFRα/β
44 Zalypsis
45 Zalypsis activity
46 Zalypsis determinants
47 Zalypsis resistance
48 activation
49 active form
50 active tyrosine kinase receptor
51 activity
52 biomarkers
53 cancer
54 cell lines
55 clinical trials
56 compounds
57 consideration
58 constitutive phosphorylation
59 culture
60 cytotoxicity
61 cytotoxicity of Zalypsis
62 data
63 determinants
64 diverse solid tumor cell lines
65 drug sensitivity data
66 drugs
67 endometrial cancer
68 expression levels
69 form
70 future clinical trials
71 high levels
72 identification
73 identification of biomarkers
74 important signal
75 kinase receptors
76 kit
77 levels
78 lines
79 low levels
80 marine compounds
81 model
82 molecular data
83 molecular signatures
84 multiple myeloma
85 myeloma
86 new panel
87 observations
88 panel
89 patients
90 phase II clinical trial
91 phosphorylation
92 prediction
93 receptors
94 resistance
95 response
96 results
97 sarcoma
98 sarcoma cell lines
99 sensitivity
100 sensitivity data
101 set
102 signals
103 signatures
104 solid tumor cell lines
105 spectra
106 spectrum of tumors
107 study
108 therapy
109 trials
110 tumor cell lines
111 tumor response
112 tumors
113 tyrosine kinase receptors
114 vivo
115 vivo xenograft studies
116 xenograft model
117 xenograft studies
118 schema:name Levels of active tyrosine kinase receptor determine the tumor response to Zalypsis
119 schema:pagination 281-281
120 schema:productId N53a1a37adb9f42bb8e1fd3f1c5000b68
121 N680f8bf375914df398f4f7116ba84825
122 N8bde8069493e4c0f80bc5da82198b820
123 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017901424
124 https://doi.org/10.1186/1471-2407-14-281
125 schema:sdDatePublished 2022-01-01T18:34
126 schema:sdLicense https://scigraph.springernature.com/explorer/license/
127 schema:sdPublisher N53aa15e5976445f7a55426c93325f7a6
128 schema:url https://doi.org/10.1186/1471-2407-14-281
129 sgo:license sg:explorer/license/
130 sgo:sdDataset articles
131 rdf:type schema:ScholarlyArticle
132 N02ebeb27d52c4fa6bf3173dc7f622906 rdf:first sg:person.0742563255.13
133 rdf:rest N8539ffbee5ab44fc9bd669684e83d25e
134 N14eb9dd0631345d0ac682e7f51f92c63 rdf:first sg:person.01047632264.90
135 rdf:rest N40a03ca8d6b143eead2bf3eb3c6320bb
136 N16b6428a6b9e41e9bf7fecdc23f2e240 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Receptor, Platelet-Derived Growth Factor alpha
138 rdf:type schema:DefinedTerm
139 N1d1e90f69cc74498801cfcbf5bc1eb0a rdf:first Ndc06ddc021ff4bb38cb2b5c1adbe9403
140 rdf:rest N2134bc4f62c647af992c1ac99be1f852
141 N2134bc4f62c647af992c1ac99be1f852 rdf:first sg:person.01367534053.35
142 rdf:rest N02ebeb27d52c4fa6bf3173dc7f622906
143 N2353b2770a9f483c8033b9e20da01140 rdf:first sg:person.0730234600.98
144 rdf:rest N1d1e90f69cc74498801cfcbf5bc1eb0a
145 N275072d834174d899b2cfd010242ad13 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Proto-Oncogene Proteins c-kit
147 rdf:type schema:DefinedTerm
148 N3f96fc3685b74276b8e198b152346bfc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Humans
150 rdf:type schema:DefinedTerm
151 N40a03ca8d6b143eead2bf3eb3c6320bb rdf:first sg:person.01300502421.68
152 rdf:rest N899b681abf5a436c832c01162174ca56
153 N53a1a37adb9f42bb8e1fd3f1c5000b68 schema:name pubmed_id
154 schema:value 24758355
155 rdf:type schema:PropertyValue
156 N53aa15e5976445f7a55426c93325f7a6 schema:name Springer Nature - SN SciGraph project
157 rdf:type schema:Organization
158 N5912e194a3cd411bbb44fea29ebf2c6d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name ErbB Receptors
160 rdf:type schema:DefinedTerm
161 N5ca76fd3219e4162b9d14b0e5366322c rdf:first sg:person.0625224764.89
162 rdf:rest N14eb9dd0631345d0ac682e7f51f92c63
163 N680f8bf375914df398f4f7116ba84825 schema:name dimensions_id
164 schema:value pub.1017901424
165 rdf:type schema:PropertyValue
166 N6eecc2f953774b3b9a19c27eea1b42ea schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Biomarkers, Pharmacological
168 rdf:type schema:DefinedTerm
169 N77fbe71aeec44ebfaf9d542c894c0a79 schema:issueNumber 1
170 rdf:type schema:PublicationIssue
171 N7b18d15639684cc6800f6d87e9c9257d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
172 schema:name Sarcoma
173 rdf:type schema:DefinedTerm
174 N7d789e3551f84f72a86266bea79e0729 schema:volumeNumber 14
175 rdf:type schema:PublicationVolume
176 N8539ffbee5ab44fc9bd669684e83d25e rdf:first sg:person.0634426643.41
177 rdf:rest rdf:nil
178 N899b681abf5a436c832c01162174ca56 rdf:first sg:person.01135361171.83
179 rdf:rest N2353b2770a9f483c8033b9e20da01140
180 N8bde8069493e4c0f80bc5da82198b820 schema:name doi
181 schema:value 10.1186/1471-2407-14-281
182 rdf:type schema:PropertyValue
183 N9cea90a27b944b1fa71890c7ded6d07b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name RNA, Messenger
185 rdf:type schema:DefinedTerm
186 Naefd942a482845a0a200df0838cefa6c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
187 schema:name Drug Resistance, Neoplasm
188 rdf:type schema:DefinedTerm
189 Nb9913c76f91942e7a463fe295a234d32 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
190 schema:name Gene Expression Regulation, Neoplastic
191 rdf:type schema:DefinedTerm
192 Nbde0aafb0ec146228ea12a3354db74c9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
193 schema:name Cell Line, Tumor
194 rdf:type schema:DefinedTerm
195 Ncccd093b01ce433489b1f62fb8ca1722 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
196 schema:name Xenograft Model Antitumor Assays
197 rdf:type schema:DefinedTerm
198 Nd1e3653907f944189b160f99e2b74d89 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
199 schema:name Receptor, Platelet-Derived Growth Factor beta
200 rdf:type schema:DefinedTerm
201 Nda822042e70b4d09b9b28db2d41c6c77 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
202 schema:name Tetrahydroisoquinolines
203 rdf:type schema:DefinedTerm
204 Ndc06ddc021ff4bb38cb2b5c1adbe9403 schema:affiliation grid-institutes:None
205 schema:familyName Santamaría
206 schema:givenName Gemma
207 rdf:type schema:Person
208 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
209 schema:name Medical and Health Sciences
210 rdf:type schema:DefinedTerm
211 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
212 schema:name Oncology and Carcinogenesis
213 rdf:type schema:DefinedTerm
214 sg:journal.1024632 schema:issn 1471-2407
215 schema:name BMC Cancer
216 schema:publisher Springer Nature
217 rdf:type schema:Periodical
218 sg:person.01047632264.90 schema:affiliation grid-institutes:grid.7719.8
219 schema:familyName Serelde
220 schema:givenName Beatriz G
221 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01047632264.90
222 rdf:type schema:Person
223 sg:person.01135361171.83 schema:affiliation grid-institutes:grid.7719.8
224 schema:familyName Diaz-Uriarte
225 schema:givenName Ramon
226 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01135361171.83
227 rdf:type schema:Person
228 sg:person.01300502421.68 schema:affiliation grid-institutes:grid.7719.8
229 schema:familyName Blanco-Aparicio
230 schema:givenName Carmen
231 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01300502421.68
232 rdf:type schema:Person
233 sg:person.01367534053.35 schema:affiliation grid-institutes:None
234 schema:familyName Tercero
235 schema:givenName Juan C
236 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01367534053.35
237 rdf:type schema:Person
238 sg:person.0625224764.89 schema:affiliation grid-institutes:None
239 schema:familyName Moneo
240 schema:givenName Victoria
241 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0625224764.89
242 rdf:type schema:Person
243 sg:person.0634426643.41 schema:affiliation grid-institutes:grid.411109.c
244 schema:familyName Carnero
245 schema:givenName Amancio
246 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0634426643.41
247 rdf:type schema:Person
248 sg:person.0730234600.98 schema:affiliation grid-institutes:None
249 schema:familyName Avilés
250 schema:givenName Pablo
251 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0730234600.98
252 rdf:type schema:Person
253 sg:person.0742563255.13 schema:affiliation grid-institutes:None
254 schema:familyName Cuevas
255 schema:givenName Carmen
256 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0742563255.13
257 rdf:type schema:Person
258 sg:pub.10.1007/s00280-008-0843-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033399730
259 https://doi.org/10.1007/s00280-008-0843-2
260 rdf:type schema:CreativeWork
261 sg:pub.10.1038/91008 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052456061
262 https://doi.org/10.1038/91008
263 rdf:type schema:CreativeWork
264 sg:pub.10.1038/nature04296 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028145633
265 https://doi.org/10.1038/nature04296
266 rdf:type schema:CreativeWork
267 sg:pub.10.1038/sj.onc.1204984 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027899748
268 https://doi.org/10.1038/sj.onc.1204984
269 rdf:type schema:CreativeWork
270 sg:pub.10.1038/sj.onc.1205181 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002286113
271 https://doi.org/10.1038/sj.onc.1205181
272 rdf:type schema:CreativeWork
273 sg:pub.10.1038/sj.onc.1207111 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041430673
274 https://doi.org/10.1038/sj.onc.1207111
275 rdf:type schema:CreativeWork
276 sg:pub.10.1038/sj.onc.1210846 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040117116
277 https://doi.org/10.1038/sj.onc.1210846
278 rdf:type schema:CreativeWork
279 sg:pub.10.1186/1471-2407-12-514 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045289283
280 https://doi.org/10.1186/1471-2407-12-514
281 rdf:type schema:CreativeWork
282 sg:pub.10.2165/00148581-200810050-00005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022748194
283 https://doi.org/10.2165/00148581-200810050-00005
284 rdf:type schema:CreativeWork
285 grid-institutes:None schema:alternateName PharmaMar R & D, Madrid, Spain
286 schema:name PharmaMar R & D, Madrid, Spain
287 rdf:type schema:Organization
288 grid-institutes:grid.411109.c schema:alternateName Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocio, Edificio IBIS, Consejo Superior de Investigaciones Cientificas, Avda. Manuel Siurot s/n., Sevilla 41013, Spain
289 schema:name Consejo Superior de Investigaciones Cientificas, Sevilla, Spain
290 Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocio, Edificio IBIS, Consejo Superior de Investigaciones Cientificas, Avda. Manuel Siurot s/n., Sevilla 41013, Spain
291 Instituto de Biomedicina de Sevilla, IBIS/Hospital Universitario Virgen del Rocio/CSIC/Universidad de Sevilla, Sevilla, Spain
292 rdf:type schema:Organization
293 grid-institutes:grid.7719.8 schema:alternateName Experimental Therapeutics Programme, Spanish National Cancer Center (CNIO), Madrid, Spain
294 Structural Biology and Biocomputing Programme, Spanish National Cancer Center (CNIO), Madrid, Spain
295 schema:name Experimental Therapeutics Programme, Spanish National Cancer Center (CNIO), Madrid, Spain
296 Structural Biology and Biocomputing Programme, Spanish National Cancer Center (CNIO), Madrid, Spain
297 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...